Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942087 | 0.90 | ALDH1A1 (0.46) | ADRB1ADRB3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2943477 | 0.89 | ADRB1 (0.45) | ADRB1ADRB3ROCK2ROCK1ALDH1A1 | |
| SCHEMBL2943838 | 0.86 | CYP1A2 (0.50) | ADRB1ADRB3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2949356 | 0.86 | ADRB1 (0.51) | ADRB1ADRB3EGFRL3MBTL1BCL2 | |
| SCHEMBL7676021 | 0.84 | ACHE (0.48) | ADRB1ADRB3ROCK2ROCK1EGFR | |
| SCHEMBL2952155 | 0.79 | CDK8 (0.50) | ADRB1ADRB3ROCK2ROCK1EGFR | |
| SCHEMBL2948776 | 0.79 | ALDH1A1 (0.45) | ADRB1ADRB3ALDH1A1KDM4EEGFR | |
| SCHEMBL2948803 | 0.76 | CYP3A4 (0.49) | ADRB1ADRB3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2943626 | 0.76 | CHEK1 (0.48) | ADRB1ADRB3CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL2949555 | 0.76 | AKR1C3 (0.45) | ADRB1ADRB3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ADRB1 4573/4885ADRB3 4640/4885CYP1A2 4316/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ADRB1 4520/4885ADRB3 4671/4885CYP1A2 4151/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | ADRB1 4702/4885ADRB3 4615/4885CYP1A2 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.